Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms - PubMed (original) (raw)

Randomized Controlled Trial

Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms

Raymond F Anton et al. J Clin Psychopharmacol. 2009 Aug.

Abstract

Improved treatment of alcohol dependence is a high priority, including defining subtypes that might respond differently. We evaluated a medication combination of intravenous flumazenil (FMZ) and oral gabapentin (GBP) in alcoholics who did and did not exhibit pretreatment alcohol withdrawal (AW) symptoms. Sixty alcohol-dependent individuals (44 with low AW and 16 with high AW) were randomized to receive FMZ (2 mg of incremental bolus for 20 minutes for 2 consecutive days) and GBP (up to 1200 mg nightly for 39 days) or their inactive placebos. Alcohol withdrawal was measured for the first 2 days, and drinking, sleep parameters, and adverse events were monitored during weekly evaluations, along with behavioral counseling sessions. Percent days abstinent (PDA) during treatment and time to first heavy drinking (TFHD) day were primary outcome variables. There was an interaction between the pretreatment AW status and the medication group on PDA (P = 0.0006) and TFHD (P = 0.06). Those in the high AW group had more PDA and more TFHD if treated with active medications, whereas those in the low AW group had more PDA and more TFHD if treated with placebo. This interaction remained for those totally abstinent (P = 0.03) and was confirmed by percent carbohydrate-deficient transferrin values. In addition, the pattern of response remained up to 8 weeks after treatment. In addition, in those with high AW, greater improvement in AW symptoms was observed in the active medication group compared with the placebo group. These results suggest a differential response to FMZ/GBP treatment, depending on pretreatment AW status that should be taken into account during future treatment trials.

PubMed Disclaimer

Cited by

Medications for unhealthy alcohol use: across the spectrum.
O'Malley SS, O'Connor PG. O'Malley SS, et al. Alcohol Res Health. 2011;33(4):300-12. Alcohol Res Health. 2011. PMID: 23580015 Free PMC article. Review.
Psychiatric Uses of Gabapentin.
Martin JC, Gainer D. Martin JC, et al. Innov Clin Neurosci. 2022 Jul-Sep;19(7-9):55-60. Innov Clin Neurosci. 2022. PMID: 36204172 Free PMC article. Review.
A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients.
Fertig JB, Ryan ML, Falk DE, Litten RZ, Mattson ME, Ransom J, Rickman WJ, Scott C, Ciraulo D, Green AI, Tiouririne NA, Johnson B, Pettinati H, Strain EC, Devine E, Brunette MF, Kampman K, A Tompkins D, Stout R; NCIG 002 Study Group. Fertig JB, et al. Alcohol Clin Exp Res. 2012 Aug;36(8):1421-30. doi: 10.1111/j.1530-0277.2011.01716.x. Epub 2012 Feb 10. Alcohol Clin Exp Res. 2012. PMID: 22324516 Free PMC article. Clinical Trial.
Current and potential pharmacological treatment options for insomnia in patients with alcohol use disorder in recovery.
Roehrs TA, Auciello J, Tseng J, Whiteside G. Roehrs TA, et al. Neuropsychopharmacol Rep. 2020 Sep;40(3):211-223. doi: 10.1002/npr2.12117. Epub 2020 Jun 15. Neuropsychopharmacol Rep. 2020. PMID: 32543111 Free PMC article. Review.
Reward, Relief and Habit Drinking: Initial Validation of a Brief Assessment Tool.
Grodin EN, Bujarski S, Venegas A, Baskerville WA, Nieto SJ, Jentsch JD, Ray LA. Grodin EN, et al. Alcohol Alcohol. 2019 Dec 1;54(6):574-583. doi: 10.1093/alcalc/agz075. Alcohol Alcohol. 2019. PMID: 31557278 Free PMC article.

Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms - PubMed (original) (raw)